Dimebon did nothing to improve the cognitive abilities of Alzheimer's
(The current failed trial was in mild to moderate Alzheimer's cases)Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
DONATE NOW
Your Alzheimer's donation will help billions live without it.
DONATE NOW
Pfizer Inc. said Wednesday that its Alzheimer's drug candidate Dimebon did not meet its goal in a late stage clinical study, as the drug was no better than a placebo at treating the disease.
The compound Dimebon did not meet any of its main or secondary goals in the study, which involved 598 patients with mild to moderate Alzheimer's disease. Dimebon is considered one of Pfizer's key drug candidates and the company is running four other late stage trials of the drug. To get more: http://abcnews.go.com
The compound Dimebon did not meet any of its main or secondary goals in the study, which involved 598 patients with mild to moderate Alzheimer's disease. Dimebon is considered one of Pfizer's key drug candidates and the company is running four other late stage trials of the drug. To get more: http://abcnews.go.com
Reduce inflammatory response in the brain
Researchers at the University of Illinois report this week that a plant compound found in abundance in celery and green peppers can disrupt a key component of the inflammatory response in the brain. The findings have implications for research on aging and diseases such as Alzheimer’s and multiple sclerosis. ...http://www.news.illinois.edu
No comments:
Post a Comment